PubRank

Ju-Seog Lee

Author PubWeight™ 122.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009 5.68
2 Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010 4.95
3 Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006 3.95
4 Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006 3.95
5 Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010 3.10
6 A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010 2.59
7 Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007 2.53
8 Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 2012 2.40
9 Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011 2.36
10 Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell 2011 2.10
11 LIN28B promotes colon cancer progression and metastasis. Cancer Res 2011 2.05
12 Functional genomics of hepatocellular carcinoma. Hepatology 2006 2.02
13 Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2006 1.98
14 Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008 1.87
15 Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011 1.83
16 Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011 1.81
17 Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 2011 1.78
18 Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013 1.72
19 Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010 1.62
20 Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res 2010 1.58
21 Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011 1.52
22 Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009 1.45
23 Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009 1.43
24 Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011 1.42
25 Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 2012 1.42
26 Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 2011 1.41
27 Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008 1.41
28 Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol 2008 1.39
29 RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 2007 1.36
30 Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 2006 1.34
31 Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 2010 1.33
32 Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2011 1.32
33 Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One 2012 1.28
34 The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 2013 1.28
35 Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. Hepatology 2006 1.27
36 LIN28B promotes growth and tumorigenesis of the intestinal epithelium via Let-7. Genes Dev 2013 1.23
37 FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 2012 1.22
38 Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011 1.17
39 Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer 2004 1.13
40 Molecular prognostication of liver cancer: end of the beginning. J Hepatol 2006 1.12
41 Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection. Cancer Res 2012 1.10
42 ARAP1 regulates endocytosis of EGFR. Traffic 2008 1.10
43 Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst 2011 1.08
44 HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest 2012 1.07
45 Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett 2013 1.04
46 Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med 2012 1.03
47 ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res 2011 1.02
48 Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer 2011 1.02
49 GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 2011 0.98
50 Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 2011 0.97
51 Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 2013 0.96
52 Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther 2012 0.96
53 Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World J Gastroenterol 2013 0.96
54 Spontaneous differentiation of mouse embryonic stem cells in vitro: characterization by global gene expression profiles. Biochem Biophys Res Commun 2005 0.94
55 Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology 2006 0.94
56 Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 2012 0.92
57 nc886, a non-coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in human gastric cancer. Oncotarget 2014 0.92
58 Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice. Gastroenterology 2012 0.91
59 Systems-level analysis of gene expression data revealed NR0B2/SHP as potential tumor suppressor in human liver cancer. Mol Cells 2010 0.91
60 Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling. Physiol Genomics 2005 0.90
61 Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 2013 0.90
62 Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One 2009 0.90
63 Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling. J Korean Med Sci 2011 0.89
64 Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 2003 0.89
65 ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 2013 0.88
66 Protein L-isoaspartyl methyltransferase regulates p53 activity. Nat Commun 2012 0.88
67 Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar. Am J Pathol 2011 0.88
68 First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011 0.86
69 Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 2012 0.86
70 Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol 2010 0.86
71 Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics 2007 0.86
72 Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR). PLoS One 2010 0.85
73 Oligonucleotide microarray analysis of aminoallyl-labeled cDNA targets from linear RNA amplification. Biotechniques 2004 0.85
74 A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia 2010 0.84
75 c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem 2011 0.84
76 Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. Carcinogenesis 2012 0.83
77 Heterologous tissue culture expression signature predicts human breast cancer prognosis. PLoS One 2007 0.81
78 CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines. Liver Int 2013 0.80
79 HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett 2013 0.79
80 3,3'-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep 2012 0.79
81 DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 2016 0.78
82 An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) 2012 0.78
83 Acquired genetic and functional alterations associated with transforming growth factor beta type I resistance in Hep3B human hepatocellular carcinoma cell line. J Cell Mol Med 2009 0.78
84 Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol 2011 0.76
85 Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology 2014 0.76
86 Reply: To PMID 22105560. Hepatology 2013 0.75
87 In silico analysis of genomic data for construction of nuclear receptor network. Methods Mol Biol 2014 0.75